A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults (NCT06047457)
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport® for the Prevention of Episodic Migraine in Adult Participants
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches. Migraines are caused by a series of events which cause the brain to get stimulated / activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 3 periods: 1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either a dose "A" or a dose ''B'' of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B"). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months).
Who can join: Review the eligibility criteria below.
Location: Central Research Associates — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (105 Sites)
Showing the first 25 of 105 sites.
- Central Research Associates — Birmingham, Alabama
- CCT Research — Phoenix, Arizona
- HonorHealth Neurology — Scottsdale, Arizona
- Hope Clinical Research, LLC — Canoga Park, California
- Axiom Research LLC — Colton, California
- Fullerton Neurological Center — Fullerton, California
- Neurology Center of North Orange County — Fullerton, California
- SDS Clinical Trials — Orange, California
- Alliance Clinical San Diego (Acclaim Clinical Research) — San Diego, California
- The Los Angeles Headache Center — Savannah, California
- Yale University School of Medicine — East Hartford, Connecticut
- Hasbani Neurology — New Haven, Connecticut
- New England Institute for Neurology and Headache (NEINH)/Medical Practice — Stamford, Connecticut
- Visionary Investigators Network (VIN) — Aventura, Florida
- Velocity Clinical Research - Hallandale Beach — Hallandale, Florida
- AGA Clinical Trials — Hialeah, Florida
- Infinity Clinical Research, LLC — Hollywood, Florida
- Clinical Neuroscience Solutions Healthcare, Inc (CNS Healthcare, INC) — Jacksonville, Florida
- 840042 — Miami, Florida
- Quantum Clinical Trials — Miami Beach, Florida
- Clinical Neuroscience Solutions, Inc ((CNS Healthcare) - Psychiatry) — Orlando, Florida
- Guardian Angel Research Center — Tampa, Florida
- Boston Clinical Trials Inc — Winter Park, Florida
- Conquest Research — Winter Park, Florida
- Cedar Crosse Research Center — Chicago, Illinois
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Episodic Migraine
- A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine — Huntsville, Alabama
- Efficacy of Nerve Blocks for Episodic Migraine — Rochester, Minnesota
- Chiropractic Care for Episodic Migraine — Boston, Massachusetts
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine — Huntsville, Alabama
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine — Chandler, Arizona
Explore by condition: All Episodic Migraine clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.